Content about GlaxoSmithKline

August 23, 2012

A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

SPRING HOUSE, Pa. — A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

August 17, 2012

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


Both of those antacid heavy hitters are losing dollar share to their generic-
equivalent competitors, however, leaving GlaxoSmithKline’s venerable Tums brand as the largest growth brand within antacids ($91.3 million in sales, up 2.5%).


August 14, 2012

The Food and Drug Administration has approved the formulation for the 2012-2013 flu vaccine, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the formulation for the 2012-2013 flu vaccine, the agency said Monday.

The agency's approval is for all six licensed flu vaccines for the 2012-2013 season: Afluria, made by CSL; Fluarix, made by GlaxoSmithKline; FluLaval, made by ID Biomedical; FluMist, made by MedImmune Vaccines; Fluvirin, made by Novartis; and Fluzone, made by Sanofi.

August 7, 2012

A new quality improvement initiative that aims to disseminate newly designed patient medication information to patients filling prescriptions at participating pharmacies has been launched.

ST. PETERSBURG, Fla. — A new quality improvement initiative that aims to disseminate newly designed patient medication information to patients filling prescriptions at participating pharmacies has been launched.

July 31, 2012

Following regulatory approval by the Food and Drug Administration's Center for Biologics Evaluation and Research, GlaxoSmithKline confirmed it has begun shipping the first lots of its 2012-2013 seasonal influenza vaccines to healthcare providers and Centers for Disease Control and Prevention distribution centers.

PHILADELPHIA — Following regulatory approval by the Food and Drug Administration's Center for Biologics Evaluation and Research, GlaxoSmithKline confirmed it has begun shipping the first lots of its 2012-2013 seasonal influenza vaccines to healthcare providers and Centers for Disease Control and Prevention distribution centers.

July 30, 2012

Stiefel, a GlaxoSmithKline company, announced the availability of Sorilux foam by prescription.

LONDON — Stiefel, a GlaxoSmithKline company, announced the availability of Sorilux foam by prescription.

The product is a topical treatment of plaque psoriasis in patients ages 18 years or older. Sorilux foam utilizes VersaFoam technology. VersaFoam-AEF (aqueous-based emulsion formulation) is free of ethanol, preservatives, parabens and fragrance, Stiefel said. The company also noted the foam is the only vitamin D3 analog treatment in a topical foam formulation.

July 30, 2012

As reported by Drug Store News, toothpastes that aim to better deliver such 
value-added benefits as teeth whitening and relieving tooth sensitivity are resonating with consumers, so the lift in sales of such products comes as little surprise.


As reported by Drug Store News, toothpastes that aim to better deliver such 
value-added benefits as teeth whitening and relieving tooth sensitivity are resonating with consumers, so the lift in sales of such products comes as little surprise.


According to SymphonyIRI Group, sales of toothpaste were essentially flat for the 12 weeks ended June 10 at food, drug and mass (excluding Walmart). However, those products that experienced double-digit sales gains included Sensodyne ProNamel (up 30.8%) and Crest 3D White (up 22.2%).

 

 

July 16, 2012

British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.

LONDON — British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.

The deal, worth $14.25 per share, would give GSK full ownership of the lupus drug Benlysta (belimumab), as well as albiglutide, an experimental drug for diabetes, and darapladib, an experimental heart disease drug.

July 16, 2012

Prestige Brands earlier this year completed its acquisition of 17 GlaxoSmithKline brands. Drug Store News sat with Prestige SVP sales and marketing Tim Connors to discuss what’s next.


Prestige Brands earlier this year completed its acquisition of 17 GlaxoSmithKline brands. Drug Store News sat with Prestige SVP sales and marketing Tim Connors to discuss what’s next.


DSN: What is the next step? 


Tim Connors: Our strategic value creation plan consists of three components: 


July 13, 2012

GlaxoSmithKline and Theravance submitted a regulatory application to the Food and Drug Administration for their chronic obstructive pulmonary disease treatment.

LONDON and SOUTH SAN FRANCISCO, Calif. — GlaxoSmithKline and Theravance submitted a regulatory application to the Food and Drug Administration for their chronic obstructive pulmonary disease treatment.

July 9, 2012

GlaxoSmithKline on Monday issued an email blast to registrants of its MyAlli.com site that Alli will be making its way back to store shelves later this month.

PITTSBURGH — GlaxoSmithKline on Monday issued an email blast to registrants of its MyAlli.com site that Alli will be making its way back to store shelves later this month.

June 21, 2012

This may be the year of the legacy brands as two companies that recently acquired separate brand portfolios from GlaxoSmithKline focus on reinvigorating consumer attention to their respective product lines.


This may be the year of the legacy brands as two companies that recently acquired separate brand portfolios from GlaxoSmithKline focus on reinvigorating consumer attention to their respective product lines.


Prestige Brands will be adding 17 former GSK brands to its stable of legacy brands that already includes Luden’s and Dramamine. The company recently identified the five key GSK-acquired brands that Prestige will be focusing on in terms of both marketing support and new product development — BC, Goody’s, Debrox, Gaviscon and Beano.


June 15, 2012

GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.

PHILADELPHIA — GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.

MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid conjugate vaccine) is approved for use in children ages six weeks through 18 months. The vaccination schedule is a four-dose series given at two, four, six, and 12 through 15 months of age.

June 14, 2012

Stiefel, a GlaxoSmithKline company, on Monday acquired the eczema remedy Toctino (alitretinoin) from Basilea Pharmaceutica.

LONDON — Stiefel, a GlaxoSmithKline company, on Monday acquired the eczema remedy Toctino (alitretinoin) from Basilea Pharmaceutica.

“Toctino is an important and growing product that complements the Stiefel portfolio and offers a proven therapy for patients with a significant unmet medical need," stated Simon Jose, Stiefel president. "This acquisition gives us an immediate opportunity to develop and expand the availability of this new and innovative product of value, and reinforces Stiefel and GSK’s commitment to dermatology.”

June 11, 2012

GlaxoSmithKline again has extended an unsolicited tender offer to acquire Human Genome Sciences.

ROCKVILLE, Md. — GlaxoSmithKline again has extended an unsolicited tender offer to acquire Human Genome Sciences.

HGS, which previously rejected an unsolicited bid from GSK, said the latest bid, which was extended Friday, is a tender offer to acquire all of the outstanding shares of HGS for $13 per share. HGS said that the offer price is inadequate and "does not reflect the value inherent in [the company]."

June 7, 2012

Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

Dr. Reddy's introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.

The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.

June 7, 2012

The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.

NEW YORK — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.

The drug makers announced Thursday the approval of Horizant (gabapentin enacarbil) extended-release tablets for managing post-herpetic neuralgia. The drug already had FDA approval for treating restless legs syndrome. The approval entitles XenoPort to a $10 million milestone payment from GSK, according to a collaborative agreement between the two companies.

June 4, 2012

One month after GlaxoSmithKline announced its tender offer to acquire Human Genome Sciences, HGS said Friday that its board of directors has rejected the unsolicited bid.

ROCKVILLE, Md. — One month after GlaxoSmithKline announced its tender offer to acquire Human Genome Sciences, HGS said Friday that its board of directors has rejected the unsolicited bid.

May 23, 2012

The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

NEW YORK — The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

Stiefel announced the approval of Fabior (tazarotene) foam in the 0.1% strength, calling it the only retinoid in a topical foam for treating acne in patients ages 12 years and older.

"Stiefel is dedicated to meeting th needs of patients and dermatologists, and we believe Fabior foam will be an important treatment option for people with moderate-to-severe acne," Stiefel VP North America dermatology Jean-Christophe May said.

May 21, 2012

The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

MALVERN, Pa. — The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

GSK and Auxilium announced an agreement for the co-promotion of Testim 1% (testosterone gel), used in men with conditions related to deficiency or absence of the hormone.

May 18, 2012

The Food and Drug Administration has approved a treatment for Parkinson's disease made by Actavis, the drug maker said Friday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a treatment for Parkinson's disease made by Actavis, the drug maker said Friday.

Actavis, which last month signed a deal with Watson Pharmaceuticals to be acquired for $5.6 billion, announced the approval and launch of ropinirole extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths.

The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of about $59.4 million in 2011, according to IMS Health.

May 17, 2012

Prestige Brands closed out its fiscal 2012 ended March 31 on a high note with $441.1 million in revenues for the year, up 31.1%. And fiscal 2013 is looking promising as the company will have full-year contributions from its 17 acquired over-the-counter brands from GlaxoSmithKline.

IRVINGTON, N.Y. — Prestige Brands closed out its fiscal 2012 ended March 31 on a high note with $441.1 million in revenues for the year, up 31.1%. And fiscal 2013 is looking promising as the company will have full-year contributions from its 17 acquired over-the-counter brands from GlaxoSmithKline.

May 16, 2012

Appropriately promoting niche brands within the intimacy health space can be a little trickier than the average consumer packaged goods product. And social media isn’t necessarily the ideal platform — an adult may not be as comfortable “liking” an intimacy enhancement product on Facebook to show their brand affinity, for example. 


Appropriately promoting niche brands within the intimacy health space can be a little trickier than the average consumer packaged goods product. And social media isn’t necessarily the ideal platform — an adult may not be as comfortable “liking” an intimacy enhancement product on Facebook to show their brand affinity, for example. 


May 15, 2012

GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

LONDON — GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

The British drug maker announced that it would buy the shares of Cellzome it doesn't already own for $99 million. Cellzome has labs in the United Kingdom and Germany, and will become part of GSK's research and development organization. The company, of which GSK currently owns 19.98%, develops technologies for profiling compounds in cells and patient samples.

May 11, 2012

GlaxoSmithKline is moving forward with its acquisition of Human Genome Sciences.

LONDON — GlaxoSmithKline is moving forward with its acquisition of Human Genome Sciences.

The drug maker said Thursday that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash, a premium of 81% to HGS's closing share price of $7.17 per share on April 18, the last trading day before HGS publicly disclosed GSK's private offer.